Oncopeptides completes patient enrollment in phase 2 PORT study
News provided by
Share this article
Share this article
STOCKHOLM, May 5, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT study. The PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma. Oncopeptides expects topline data in Q3 2021. I am very pleased that we have enrolled the final patient in the PORT study, said Klaas Bakker, MD, PhD and Chief Medical Officer at Oncopeptides. The data could potentially provide a pathway for us to work with the U.S. Food and Drug Administration to
$10 Million Gift to Open Kimberly and Eric J Waldman Melanoma and Skin Cancer Center at Mount Sinai miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
New York– A new personalised cancer vaccine, developed by the US researchers, is safe and beneficial for patients with different cancers, including lung and bladder, results of phase I clinical trials have shown.
“While immunotherapy has revolutionised the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments,” said Thomas Marron, Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai, in New York, US.A
“Cancer vaccines, which typically combine tumour-specific targets that the immune system can learn to recognise and attack to prevent recurrence of cancer. The vaccine also contains an adjuvant that primes the immune system to maximise the efficacy,” Maron said.
Personalised cancer vaccine safe and potentially beneficial to patients europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Novel personalised cancer vaccine safe: Study
By IANS |
2 Views
Novel personalised cancer vaccine safe: Study.. Image Source: IANS News
New York, April 12 : A new personalised cancer vaccine, developed by the US researchers, is safe and beneficial for patients with different cancers, including lung and bladder, results of phase I clinical trials have shown. While immunotherapy has revolutionised the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments, said Thomas Marron, Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai, in New York, US.A